MEDVi Review 2026: GLP-1 Weight Loss Telehealth, Pricing, and the FDA Picture
The Fast Facts
- MEDVi is a telehealth clinic based in Newark, Delaware, focused specifically on making GLP-1 weight-loss medications accessible and affordable.
- It offers compounded semaglutide and tirzepatide as injections, plus an unusual once-daily sublingual semaglutide tablet for people who dislike needles.
- MEDVi has a large review base but mixed feedback, operates on a cash-pay model, and received an FDA warning letter in 2026 related to its GLP-1 marketing.
GLP-1 telehealth clinics have multiplied quickly, and they vary widely in what they offer and how they handle safety and compliance. Because these are prescription medications, both the clinical model and the regulatory track record deserve a close look.
In this MEDVi review, we cover how the platform works, what it offers, the safety and FDA context, and who it may suit — presented evenhandedly and without medical advice.
A quick look at our picks
- Most popular: MEDVi Compounded Semaglutide Injection
- Strongest average results: MEDVi Compounded Tirzepatide
- For needle-free preference: MEDVi Sublingual Semaglutide Tablet
- Built-in: MEDVi Membership & Support
What is MEDVi?
MEDVi is a Delaware-based telehealth clinic that focuses exclusively on GLP-1 weight-loss support. By partnering with licensed compounding pharmacies, it provides compounded semaglutide and tirzepatide at a lower cost than brand-name products, with licensed providers evaluating eligibility online.
A distinctive feature is its once-daily sublingual semaglutide tablet, which dissolves under the tongue and is aimed at patients who have difficulty with injections. Memberships include unlimited provider visits and 24/7 messaging support, with prescriptions often delivered quickly after approval.
MEDVi programs and options
The options below are prescription programs that require approval by a licensed clinician. Eligibility depends on your medical history, and approval is not guaranteed.
MEDVi Compounded Semaglutide Injection
- Type: compounded GLP-1 (semaglutide)
- Format: subcutaneous injection
- Prescription: required after clinician review
- Note: compounded, not FDA-approved
Our review
This is MEDVi’s core offering: a compounded version of semaglutide, the active ingredient in Ozempic and Wegovy, at a lower cost than the brands. A licensed provider evaluates whether it is appropriate for you.
Because it is compounded, it is not FDA-approved and may differ in formulation from brand-name products. Side effects such as nausea are common, particularly during dose increases.
Product details
- Clinician-reviewed: yes
- Lower cost than brand: advertised
- Home delivery: fast
- 24/7 messaging: yes
MEDVi Compounded Tirzepatide
- Type: compounded GLP-1/GIP (tirzepatide)
- Format: injection or tablet
- Prescription: required after clinician review
- Note: compounded, not FDA-approved
Our review
Tirzepatide works on two hormone pathways and is associated with greater average weight loss than semaglutide for many people. MEDVi offers it in compounded form for eligible patients.
As with any GLP-1, it requires clinician approval, can cause gastrointestinal and other side effects, and is not suitable for everyone.
Product details
- Clinician-reviewed: yes
- Dual-pathway: yes
- Home delivery: fast
- Unlimited visits: yes
MEDVi Sublingual Semaglutide Tablet
- Type: compounded semaglutide, sublingual
- Format: dissolves under the tongue, once daily
- Best for: people who dislike needles
- Note: compounded, not FDA-approved
Our review
MEDVi’s sublingual tablet is its most distinctive product: a once-daily semaglutide that dissolves under the tongue, designed for patients who struggle with injections. It is a genuinely useful option for the needle-averse.
As a compounded product, it carries the same caveats around FDA approval and formulation, and a clinician should confirm it suits you.
Product details
- Needle-free: yes
- Once daily: yes
- Clinician-reviewed: yes
- Compounded: yes
MEDVi Membership & Support
- Includes: unlimited provider visits
- Support: 24/7 messaging
- Delivery: often within about a day of approval
- Model: flat-rate, cash-pay
Our review
Memberships bundle unlimited doctor visits and around-the-clock messaging, with fast delivery after approval. Many customers praise their results and the access to providers.
Reviews are mixed, though: some report billing issues and inconsistent shipping, and there is little structured nutrition or behavioral coaching for long-term habit change.
Product details
- Unlimited visits: yes
- 24/7 messaging: yes
- Cash-pay: yes
- No insurance billing: correct
Pros and cons at a glance
Pros
- focused entirely on affordable GLP-1 access
- unusual sublingual tablet option for people who dislike injections
- unlimited provider visits and 24/7 messaging included
- fast delivery after approval
- very large review base
Cons
- received an FDA warning letter in 2026 over GLP-1 marketing
- compounded medications are not FDA-approved and may vary from brand drugs
- mixed reviews, including billing and shipping complaints
- little structured nutrition or behavioral support
- cash-pay only, with no insurance assistance
How MEDVi works
You complete an online evaluation, a licensed provider reviews your eligibility, and if approved, your medication ships — often within about a day. You can also request a telehealth appointment first. Membership includes unlimited visits and 24/7 messaging, which is generous on the access side.
Approval depends on your medical history and is not guaranteed.
The 2026 FDA warning letter
In the interest of a balanced review, it is important to note that MEDVi received an FDA warning letter in 2026 related to the marketing of its GLP-1 weight-loss products. Warning letters identify concerns the agency wants a company to address; they are part of the public record and worth factoring into your decision.
This context matters because the compounded GLP-1 space as a whole has drawn regulatory scrutiny. If you are considering MEDVi, it is reasonable to review the current status directly and to discuss compounded medications with a provider.
Safety, side effects, and compounding
GLP-1 medications can cause side effects, most commonly gastrointestinal issues, and they carry contraindications that a clinician should review with you. Compounded semaglutide and tirzepatide are not FDA-approved as finished products and may differ in formulation, concentration, and quality from brand-name versions, which adds risk.
None of this means the medications cannot help eligible patients, but it does mean the decision belongs with you and a licensed provider.
Pricing and what is included
MEDVi uses a flat-rate, cash-pay model, with the injection options generally priced below the sublingual and tirzepatide tiers. Membership includes the clinical access described above. It does not bill insurance or assist with prior authorizations, so payment is out of pocket.
Because pricing and tiers change, confirm current details on the official site before enrolling.
Who MEDVi is for
MEDVi may suit adults who qualify for GLP-1 therapy, want low-cost access and lots of provider messaging, and are specifically interested in a needle-free sublingual option. It is less suited to people who want structured coaching, insurance billing, or who are uneasy about compounded medications or the recent regulatory attention.
Comparing GLP-1 telehealth platforms
| Provider | Medications | Needle-free option | Support | Model |
|---|---|---|---|---|
| MEDVi | compounded semaglutide, tirzepatide | Yes (sublingual) | unlimited visits, 24/7 | flat-rate, cash-pay |
| TrimRX | compounded + brand semaglutide, tirzepatide | No | ongoing telehealth | flat-rate, cash-pay |
| TMates | compounded semaglutide, tirzepatide, phentermine | No | 24/7, SMS coaching | cash-pay |
| Synergy Rx | compounded semaglutide, tirzepatide | No | minimal | cash-pay |
Frequently asked questions about MEDVi
What does MEDVi offer?
Compounded semaglutide and tirzepatide as injections, plus a once-daily sublingual semaglutide tablet, with unlimited provider visits and 24/7 messaging.
Did MEDVi receive an FDA warning letter?
Yes. In 2026 MEDVi received an FDA warning letter related to the marketing of its GLP-1 weight-loss products. It is worth reviewing the current status before enrolling.
Are MEDVi’s medications FDA-approved?
No. They are compounded, which means they are not FDA-approved as finished products and may differ from brand-name drugs.
Does MEDVi take insurance?
No. It operates on a cash-pay model and does not bill insurance or handle prior authorizations.
Is the sublingual tablet a good option?
It is designed for people who dislike injections. Whether it is right for you is a decision for you and a licensed clinician.
The takeaway
MEDVi stands out for affordable GLP-1 access, generous provider messaging, and an unusual needle-free sublingual option. But a balanced view has to weigh the trade-offs: its medications are compounded rather than FDA-approved, reviews are mixed on billing and shipping, structured coaching is limited, and the company received an FDA warning letter in 2026 over its GLP-1 marketing. If you are exploring medical weight loss, MEDVi is one option among several — one to evaluate carefully, with current regulatory status checked and a licensed healthcare provider guiding the decision.
Disclaimer
This article is for informational purposes only and is not medical advice. GLP-1 medications are prescription drugs with potential side effects and contraindications; compounded versions are not FDA-approved as finished products. Mention of a regulatory action is factual context, not a legal conclusion. Nothing here is a recommendation to start, stop, or change any medication. Always consult a licensed healthcare provider, and review current FDA guidance on compounded GLP-1 medications. Details may change; verify on the provider’s official site. This article may contain affiliate links, and all brand names belong to their respective owners.
